Protara Therapeutics, Inc. — Director's Dealing 2018

Feb 16, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2018-02-14

Reporting Person: NOYES TIMOTHY P (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-02-14	Common Stock	D	3500	$2.20	Disposed	5242	Direct
2018-02-15	Common Stock	D	2245	$2.152	Disposed	2997	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2017.

F2: The selling price of $2.20 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $2.20 to $2.23. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The selling price of $2.152 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $2.10 to $2.25. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.